SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma

Completed · Not applicable

Conditions studied: Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ

In brief

The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR. Tumor core biopsies will be processed and analyzed as described above. Medical records electronic medical records will be used to collect demographic and medical information and imaging studies.

Key facts

Study ID

NCT02986867

Run by

University of Texas Southwestern Medical Center

People needed

27

Starts

2017-06-13

Expected to finish

2018-03-07

Last updated by the study team

2019-01-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic diagnosis of advanced/metastatic urothelial carcinoma, melanoma, or cervical carcinoma.
• Planned treated with SAbR.
• Age greater than or equal to 18 years.
• Lesion to receive SAbR safely accessible for core biopsy-mass >1.5cm diameter and located in node, liver, or soft tissues.
• Hgb >10g/dL before or after transfusion.
• Platelets >50,000/L
• INR <1.5
• If contrast enhanced CT needed to locate the lesion for core biopsy, then derived creatinine clearance >30cc/min
• Ability to understand and the willingness to sign a written informed consent.

You may not qualify if…

• Prior radiation therapy to target lesion.
• Target lesion not safely accessible for core biopsies.

Where it is running

• University of Texas Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.